1-3 of 3
Jodi Prime, BSc.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2012) 120 (21): 165.
https://doi.org/10.1182/blood.V120.21.165.165
Published: 2012
Journal Articles

Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance

Susan Branford, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Jodi Prime, BSc., David Ross, MBBS, PhD, Timothy P. Hughes, MD, MBBS
Journal: Blood
Blood (2011) 118 (21): 113.
https://doi.org/10.1182/blood.V118.21.113.113
Published: 2011
Journal Articles

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Carine Tang, BSc., (Hons), Lisa Schafranek, BSc., (Hons), Dale Watkins, BSc., (Hons), Wendy T Parker, PhD, Jodi Prime, BSc., Deborah L White, PhD, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2010) 116 (21): 3383.
https://doi.org/10.1182/blood.V116.21.3383.3383
Published: 2010